cytarabine has been researched along with Chemotherapy-Induced Febrile Neutropenia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Barbon Gauro, J; Heng, MS; Thomas, J; Yaxley, A | 1 |
| Fanale, M; Fayad, LE; Feng, L; Ford, P; Fowler, N; Goy, A; Hagemeister, F; Hartig, K; Kantarjian, HM; Kwak, LW; McLaughlin, P; Medeiros, LJ; Naig, A; Neelapu, S; Oki, Y; Orlowski, R; Pro, B; Rodriguez, MA; Romaguera, JE; Samaniego, F; Smith, J; Valentinetti, M; Wang, M; Younes, A | 1 |
| Chen, C; Xu, W; Yang, J | 1 |
| Caballero, MD; Canales, M; de la Cruz, F; Domingo-Domenech, E; Garcia-Sanz, R; Gonzalez, AP; Gutierrez, A; Jimenez-Cabrera, S; Lopez, J; Martinez, C; Moreno, M; Pinana, JL; Rodriguez, A; Rodriguez, G; Rodriguez-Salazar, MJ; Sanchez-Gonzalez, B; Sureda, A | 1 |
| de Revel, T; Eddou, H; Jennane, S; Konopacki, J; Mahtat, EM; Malfuson, JV; Souleau, B | 1 |
| Ang, AL; Goh, YT; Kam, G; Loh, Y; Wong, GC; Yiu, R; Yueh, LL | 1 |
| Chen, J; Hu, J; Huang, H; Huang, X; Jin, J; Li, J; Li, Y; Liang, Y; Ma, J; Sun, Y; Wang, C; Wang, J; Wang, L; Wu, D; Xiao, Y; Yu, K | 1 |
| Choi, CW; Kang, KW; Kim, BS; Kim, DS; Kim, SJ; Lee, SR; Park, Y; Sung, HJ | 1 |
4 trial(s) available for cytarabine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Failure; Vincristine | 2018 |
Thalidomide in Combination with Chemotherapy in Treating Elderly Patients with Acute Myeloid Leukemia.
Topics: Aclarubicin; Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Outcome Assessment, Health Care; Proportional Hazards Models; Prospective Studies; Remission Induction; Thalidomide | 2018 |
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brentuximab Vedotin; Chemotherapy-Induced Febrile Neutropenia; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prednisone; Progression-Free Survival; Salvage Therapy; Transplantation, Autologous; Young Adult | 2019 |
Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy.
Topics: Adolescent; Adult; Chemotherapy-Induced Febrile Neutropenia; Consolidation Chemotherapy; Cytarabine; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
4 other study(ies) available for cytarabine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Does a neutropenic diet reduce adverse outcomes in patients undergoing chemotherapy?
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Bacterial Infections; Carmustine; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Diet Therapy; Enterocolitis, Neutropenic; Female; Hematologic Neoplasms; Humans; Idarubicin; Male; Melphalan; Middle Aged; Neutropenia; Podophyllotoxin; Retrospective Studies; South Australia | 2020 |
[Contribution of PET/CT for the management of hepatosplenic candidiasis in hematology].
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Candidiasis, Invasive; Chemotherapy-Induced Febrile Neutropenia; Cytarabine; Daunorubicin; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Hepatitis; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Radiopharmaceuticals; Splenic Diseases; Tomography, X-Ray Computed | 2014 |
Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy: A Multicenter, Prospective, Observational Study in China.
Topics: Adolescent; Adult; Anthracyclines; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Child; Child, Preschool; China; Consolidation Chemotherapy; Cytarabine; Female; Humans; Incidence; Infant; Length of Stay; Leukemia, Myeloid, Acute; Male; Middle Aged; Mycoses; Prospective Studies; Survival Rate; Vidarabine; Young Adult | 2016 |
Effect of granulocyte colony-stimulating factor on outcomes in patients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosphamide; Cytarabine; Daunorubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mercaptopurine; Middle Aged; Mortality; Remission Induction; Republic of Korea; Retrospective Studies; Treatment Outcome; Young Adult | 2017 |